Table 1.

Summary of the different studies conducted in diabetic and non-diabetic rats.

Study	Model	Procedure performed	Follow up
Bio-integration	Non-diabetic Wistar rats Diabetic Wistar rats	Intraperitoneal MailPan® implantation Intraperitoneal MailPan® implantation	• Angiography at 2 months • PET-Scan with 4000 islets in device at 3 months • Microvessels live imaging at 6 months post-implantation (all performed on the same rats) • Plasma α2-Macroglobulin at 0, 2, 4, 6 weeks post-implantation • O2 measurement at 6 weeks post-implantation • Histological analyses at the end of function study (4 months of implantation)
Function study	Diabetic rats	Intraperitoneal MailPan® implantation, pre-implantation of 6 weeks, then injection of 5.106 RIN-m5f cells/100 g	• Body weight gain • Fasting and non-fasting glycemia • Viability of cells flushed out examined after 10 weeks
Immunization Study	Non-diabetic Lewis rats	Intraperitoneal MailPan® implantation, pre-implantation of 6 weeks, then injection of 5000 IEQ from Dark Agouti rats in device	• Plasma α2-Macroglobulin levels before and after cells injection • Detection of anti-Dark Agouti Antibodies at D0 and D30 after islets injection in MailPan®

PET: positron emission tomography; IEQ: islet-equivalent.